Labetalol is the third product launched under partnership with Strides Arcolab. Under the joint venture partnership, Sagent and Strides Arcolab have been jointly developing, supplying and marketing more than 25 injectable products for the US market.
Jeffrey Yordon, founder, chairman and CEO of Sagent, said: “Another product of our joint venture with Strides Arcolab, labetalol is an important addition to our specialty injectable portfolio and enhances our cardiovascular care offering.
“Our labetalol features Sagent’s proprietary PreventIV Measures labeling and packaging. With our distinctive labeling designs and easy to read drug name and dosage information, we are striving to help reduce medication errors. Further, labetalol HCl injection is latex-free, helping to prevent potential allergic reactions in patients and health care providers.”